Table 1.

Associations between history of selected comorbidities and OS and PFS: Ovarian Cancer Association Consortium

DeceasedProgression
ComorbidityYesNoHR (95% CI)a,bYesNoHR (95% CI)a,b
Endometriosis
 No6,3564,8241.00 (ref)2,5541,3291.00 (ref)
 Yes5718530.92 (0.84–1.01)2031841.06 (0.91–1.24)
Asthma
 No2,1171,3931.00 (ref)1,4466401.00 (ref)
 Yes1251011.00 (0.84–1.20)89500.93 (0.75–1.16)
Depression
 No2,7311,6471.00 (ref)1,6697411.00 (ref)
 Yes4393080.97 (0.87–1.08)202980.90 (0.76–1.07)
Osteoporosis
 No2,0431,4051.00 (ref)1,0934451.00 (ref)
 Yes170850.95 (0.81–1.12)76210.96 (0.73–1.27)
Autoimmune disease
 No9075791.00 (ref)7843861.00 (ref)
 Yes2421780.94 (0.73–1.22)162760.95 (0.74–1.23)
Kidney disease
 No1,7391,3171.00 (ref)1,0045161.00 (ref)
 Yes48371.19 (0.89–1.60)1891.04 (0.65–1.67)
Liver disease
 No2,1861,4611.00 (ref)1,4856641.00 (ref)
 Yes31150.98 (0.68–1.41)15100.86 (0.54–1.38)
Gallbladder disease
 No2,4331,6261.00 (ref)1,4836451.00 (ref)
 Yes4382051.06 (0.96–1.18)254881.09 (0.94–1.26)
Neurological disease
 No1,1561,0311.00 (ref)5472501.00 (ref)
 Yes17111.32 (0.79–2.21)980.82 (0.41–1.68)
  • aModels adjusted for age (continuous), stage (localized, regional, or advanced), histology, and study site.

  • bStudies included for each comorbidity as presented in Supplementary Table S1.